Mumbai, Dec 4 (UNI) DSM Anti-Infective, which is a part of the global multi-speciality chemical company DSM Group, today entered into a strategic partnership with the city-based Arch Pharmalabs to jointly develop non-infringing process for generic molecules.
The partnership was announced by DSM Anti-Infective Vice President Hans Van Nistelrooij and Arch Pharmalabs Chairman and Managing Director Ajit Kamath at a joint media briefing here today.
Under the agreement, DSM will jointly develop non-infringing process for generic molecules with Arch Pharamalabs and will utilize the Arch's state-of-the-art manufacturing platform to cater to growing generic market demand.
By having the partnership, the generics portfolio of innovation molecules will contribute to the USD one billion innovation products sales target, which the DSM wants to achieve by year 2010.
''As DSM Anti Infective is now diversifying its portfolio of active pharmaceutical ingredients (API), to make this happen quicker and to be close to the fastest growing generic market in the world, we have adopted the partnership route for commercialisation of DSM's new venture into generic APIs. This manufacturing agreement will enable us further strengthen our innovation focus in India,'' Mr Nistelrooij said.
Commenting on the agreement, Mr Kamath said, ''We expect the alliance to deliver a range of products in varied therapeutic segments and take a leadership position based on cost and market reach.'' UNI